In conclusion, these results support that the antileukemic activity of BCL2 and BCR-ABL1 dual targeting does not eradicate the primitive leukemic cells in CP-CML patients but may be a useful therapeutic strategy for Ph+ ALL patients. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.